EU drug regulator does not refer to Eisai-Biogen Alzheimer’s drug in meeting notes

Mar 22,2024

London: The European Union’s medicines regulator did not mention Eisai and Biogen’s Alzheimer’s drug in its notes and recommendations on Friday.

The European Medicines Agency had said it would hold a oral hearing to discuss the drug, lecanemab, this week.

The drug, sold as Leqembi in the United States has been under review in Europe since January 2023. It gained traditional approval in the United States last year and is also approved in other countries, including China and Japan.

The infusion given twice a month removes sticky clumps of a protein called amyloid beta, believed to be a hallmark of Alzheimer’s, from the brain.

Source: Pharma

- Advertisement - To Sponser Contact Us